All four members of the human epidermal growth factor (EGF) receptor (HER) family are implicated in human cancers. Although efficacious in a subset of patients, resistance to single-targeted anti-HER therapy [i.e., cetuximab (Erbitux) and trastuzumab (Herceptin
Introduction
The human epidermal growth factor (EGF) receptor (HER) family is composed of EGFR/HER-1/ErbB1, HER-2/ErbB2, HER-3/ErbB3, and HER-4/ErbB4 (1 -3) . This family of proteins share common structural features consisting of an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic kinase domain (1, 4) . Among this family of receptors, only HER-1, HER-3, and HER-4 bind canonical growth factor ligands (1, 2, 4) . HER-1, HER-2, and HER-4 are active as tyrosine kinases, whereas HER-3, despite having a kinase domain, is inactive as a kinase and signals via the phosphatidylinositol 3-kinase pathway (1, 4 -9) . On ligand binding, these receptors dimerize to form homodimers and multiple combinations of heterodimers (1, 2, 10) . Ligand-induced dimerization results in activation of receptor tyrosine kinase activity, self-phosphorylation, recruitment and phosphorylation of several intracellular proteins, and coupling to multiple downstream signaling cascades (1, 3) . These signaling pathways include (a) the Ras-Raf-mitogen-activated protein kinase mitogenic pathway; (b) the phosphatidylinositol 3-kinase-AKT cell survival pathway; and (c) stress-activated protein kinase C and Jak/Stat (1, 3) . Signaling culminates in a variety of cellular responses including cell migration, invasion, proliferation, survival, and differentiation (1 -3) .
Besides regulating normal cell growth and differentiation, the HER family of proteins and their ligands are involved in the molecular pathogenesis of cancer when dysregulated either via elevated expression levels or through mutation (1, (11) (12) (13) . Since the initial discovery of the correlation between HER-2 overexpression and poor prognosis in breast cancer patients (14) , all other HER family members have been shown to be prognostic indicators of clinical outcome (1, 15) . Current approved drugs for the treatment of cancers driven by the HER family of proteins are either monoclonal antibodies such as trastuzumab (directed at HER-2) or cetuximab (directed at HER-1) or small-molecule tyrosine kinase inhibitors such as gefitinib and erlotinib (HER-1 kinase inhibitors) and lapatinib (dual HER-2 kinase and HER-1 kinase inhibitor; refs. 3, 10, 16, 17) . Several other monoclonal antibodies and tyrosine kinase inhibitors directed toward the HER family proteins are in clinical trials (3, 16, 17) .
Although efficacious in a subset of patients, monoclonal antibodies such as trastuzumab or tyrosine kinase inhibitors such as gefitinib, directed at only one HER family member, often encounter endogenous or acquired resistance (3, 18, 19) . This drug resistance is often associated with compensation by or up-regulation of other HER family members such as HER-3 and HER-4 (15, 20, 21) or increased production of HER-1 or HER-3 ligands by tumor cells (22, 23) . Therefore, it is critical to inhibit functions of multiple ligand-induced HER family members to achieve the broadest efficacy. Here we describe a novel approach to inhibit the function of the HER family. We designed a chimeric molecule (RB200), composed of the extracellular domain of HER-1 and HER-3 fused with the Fc domain of human IgG1. In our studies we found that RB200 (a) bound several HER-1 ligands including EGF and transforming growth factor-a and HER-3 ligands such as neuregulin 1 (NRG1)-h1 and NRG1-h3, (b) inhibited ligand-induced HER family phosphorylation, and (c) inhibited proliferation of tumor cells, including inhibition of G-proteincoupled receptor (GPCR) -induced cell proliferation and inhibition of tumor growth in xenograft models.
Materials and Methods

Reagents
Unless stated otherwise, all growth factors (recombinant, human), antibodies to HER family proteins, and antiphosphotyrosine-HRP (anti-PY-HRP) were from R&D Systems. NRG1-h3 was from Upstate/Millipore and amphiregulin was from Apollo Cytokine Research. Lysophosphatidic acid (LPA), human recombinant insulin, human recombinant insulin-like growth factor (IGF)-I, antihuman IgG-Fc polyclonal antibody, HEPES and TrisHCl buffers, hydrocortisone, crystal violet dye, and Protease Inhibitor Cocktail for general use were from Sigma-Aldrich. RPMI, McCoy's 5A, Ham's F-12, and DMEM culture media were from Mediatech, and fetal bovine serum (FBS) was from Equitech. 125 I-EGF was purchased (GE-Amersham) and NRG1-h1 (EGF domain) was custom labeled with 125 I (GE-Amersham). Europium (Eu)-labeled EGF (Eu-EGF), custom-labeled Eu-NRG1-h1, and DELFIA reagents were from Perkin-Elmer. Protein A-Sepharose, NuPAGE gels, FreeStyle 293 serum-free medium, and Lipofectamine 2000 were from Invitrogen.
Cell Lines and Tissue Culture All the human cancer cell lines used in the studies (except SUM149) were purchased from the American Type Culture Collection; SUM149 cells were from Asterand. HT-29 and SK-BR-3 cells were cultured in McCoy's 5A, NCI-N87 and ZR-75-1 cells in RPMI, and A549 and A431 cells in DMEM; all media were supplemented with 10% FBS. For cell proliferation and xenograft studies, all tumor cell lines (except SUM149 cells) were maintained in RPMI supplemented with 10% FBS, 2.0 mmol/L glutamine, 100 units/ mL penicillin-streptomycin, 10 mmol/L HEPES, 1 mmol/L sodium pyruvate, and 26 mmol/L sodium bicarbonate. Cell proliferation studies were conducted in the abovementioned RPMI medium, except that 4.0 mmol/L glutamine and 50 mmol/L sodium bicarbonate were added and HEPES buffer was excluded from the medium. SUM149 cells were cultured in Ham's F-12 medium supplemented with 5 Ag/mL insulin, 1 Ag/mL hydrocortisone, 10 mmol/L HEPES buffer, and 5% FBS. Cell proliferation studies with SUM149 cells were conducted under the above culture conditions unless stated serum-free. All cells were grown in incubators at 37jC in a humidified atmosphere with 5% CO 2 and 95% air. All cell lines were subcultured twice per week.
Cloning and Expression of Hermodulins
The extracellular domains of HER-1 (amino acids 1 -621), HER-2 (amino acids 1 -650), HER-3 (amino acids 1 -621), and HER-4 (amino acids 1 -650) were amplified by PCR from the corresponding full-length receptor cDNAs (obtained from Dr. Gail Clinton, Oregon Health Sciences University, Portland, OR). The amplified cDNA fragments were subcloned into the pcDNA3.1-MycHis expression vector (Invitrogen) via the KpnI-XhoI (HER-1, HER-2, and HER-4) or KpnI-XbaI (HER-3) restriction sites. To make HER/Fc fusion proteins, the Fc fragment of human IgG1 (from Pro 100 to Lys 330 ) was PCR amplified with a linker GRMD added NH 2 -terminally to the Fc fragment via the forward primer. The amplified Fc-encoding cDNA fragment was subsequently fused in-frame to the 3 ¶-end of HER-1, HER-2, HER-3, and HER-4 extracellular domains in the pcDNA3.1-MycHis vector via restriction digestion using the XhoI-AgeI site (for HER-1/Fc, HER-2/Fc, and HER-4/Fc) and XbaI-AgeI site (for HER-3/Fc). To remove the COOH-terminal MycHis tag from the HER/Fc fusion proteins, a stop codon was inserted upstream of the MycHis tag via PCR. To selectively retain the COOHterminal 6xHis tag on HER-3/Fc, a PCR-based deletion of the Myc tag was done. All recombinant constructs were confirmed by complete DNA sequencing.
Protein Expression Adherent cell protein expression was accomplished as follows: The HER extracellular domain/Fc constructs described above were transiently transfected into HEK 293T cells, which were cultured in DMEM with 7.5% FBS in 10-Layer Cell Factories (Corning, Inc.), using Lipofectamine 2000 following the manufacturer's instructions. To express the RB200 heterodimer, the constructs of HER-1/Fc and HER-3/Fc were cotransfected in a ratio of 1:3 (HER-1/ Fc:HER-3/Fc). After 5 h of transient transfection, the medium was replaced with DMEM containing 1% FBS (low IgG; Life Technologies, Inc./Invitrogen). First conditioned medium was collected 4 d after transient transfection, followed by feeding and a second collection of the medium. Suspension cell protein expression was done using HEK 293T cells that were previously adapted to grow in FreeStyle 293 serum-free medium. HEK 293T cells were seeded in Wave BioReactors (Wave Biotech/GE Healthcare) at 1 Â 10 6 /mL with Freestyle 293 medium. The next day, 293T cells were cotransfected with HER-1/Fc and HER-3/Fc at 1:3 ratio using 25-kDa linear PEI (Polysciences, Inc.) to express the RB200 heterodimer. Conditioned medium was collected 6 d after transient transfection.
HER1:HER3 Fc Fusion: a Novel EGFR Family Inhibitor
Protein Purification Conditioned medium from transfected cells was clarified by centrifugation followed by filtration through a 3-Am Versapore 3000T filter (Pall Corporation) and 10-fold concentration using a 30-kDa cutoff Ultrasette Screen Channel filtration (Pall Corporation) and applied to a MabSelect SuRe affinity column (GE Healthcare Biosciences AB). The column was extensively washed with PBS containing 0.1% (v/v) TX-114 and eluted with an IgG elution buffer (Pierce). The eluted fractions were immediately neutralized with 1 mol/L Tris-HCl to pH 8.0. Fc-containing proteins eluting from the MabSelect SuRe affinity column consisted of the RB200 heterodimer as well as the HFD100 and HFD300 homodimers. The RB200 heterodimer was further purified to homogeneity from the MabSelect SuRe-eluted mixture by removing contaminating HFD100 and HFD300 homodimers. The HFD100 homodimers, which lack a His-tag, were first removed by loading the mixture onto a HisTrap Fastflow column (GE Healthcare Biosciences) equilibrated in 50 mmol/L Na 2 HPO 4 (pH 8.0) and 350 mmol/L NaCl. The loaded column was washed with 35-column volumes of equilibration buffer containing 0.1% (v/v) TX-114 and eluted with a buffer composed of 50 mmol/L Na 2 HPO 4 (pH 8.0), 350 mmol/L NaCl, and 0.5 mol/L imidazole. The eluted fractions, composed of HFD300 and RB200, were pooled and buffer exchanged into PBS. The HFD300 homodimer was separated from the RB200 heterodimer by applying the sample onto an anti-EGFR-Affibody affinity column (Affibody AB) equilibrated in PBS. The loaded column was washed with 10-column volumes of PBS, eluted with IgG elution buffer (Pierce), and neutralized with 1 mol/L Tris to pH 8.0. The final RB200 pool was buffer exchanged into PBS, concentrated, and frozen at À80jC until use.
Purity Determination by Analytic Reverse-Phase High-Performance Liquid Chromatography
Reverse-phase high-performance liquid chromatography of proteins was done using an analytic C4 column (50 Â 46 Â 5 mm; 300 Å ) from Phenomenex, attached to an AKTA Purifier System (GE Healthcare). Buffer A consisted of 0.1% trifluoroacetyl or trifluoroacetic acid (v/v) in water, and buffer B consisted of 25% 2-propanol, 75% acetonitrile, and 0.1% trifluoroacetyl or trifluoroacetic acid (v/v). Typically, 25 Ag of protein were loaded and a linear gradient of 55% to 72% buffer B was used to elute samples (flow rate, 1.0 mL/min; gradient, 1.21%/min). By this reverse-phase high-performance liquid chromatography, the HER-3/Fc homodimer (HFD300) elutes first, followed by the heterodimer (RB200) and then the HER-1/Fc homodimer (HFD100). Peaks were identified using two approaches: First, standards purified from singly transfected cells (coded for only one polypeptide chain) were used to identify the homodimer peaks (Fig. 2) . Second, fractions from each peak were submitted for NH 2 -terminal sequencing (Stanford: PAN facility) to verify initial assignments (data not shown).
Radiolabeled EGF or NRG1-B1 Binding by CrossLinking Studies
Conditioned medium (20 AL) from transfected 293T cells expressing the indicated HER constructs (f20 Ag/mL) was incubated for 1 h with 125 I-EGF (5 nmol/L) or 125 I-NRG1-h1 (5 nmol/L) in 20 mmol/L HEPES buffer (pH 7.5) at 22jC. Following this, a chemical cross-linker, BS3, at 2.0 mmol/L final (Pierce) was added and cross-linking was continued for 30 min, and then reaction was terminated by the addition of 100 mmol/L (final) Tris-HCl (pH 7.5). Ligandbound HER molecules were separated by denaturing PAGE. Following this, the gels were dried and exposed to a storage phosphor screen (GE-Amersham). Radiation signals recorded on the storage phosphor screen were detected by Typhoon Trio using ImageQuest Software (GE-Amersham).
DELFIA Ligand Binding Assay
The ligand binding activities of Hermodulins were determined by the DELFIA method using Eu-labeled ligands (Eu-EGF) for HER-1 ligand binding activity and Eu-NRG1-h1 for HER-3 ligand binding activity on polyclonal antihuman IgG-Fc -coated (0.5 Ag/well/100 AL) DELFIA 96-well yellow plates (Perkin-Elmer). On the day of the assay, anti-IgG-Fc -coated plates were washed and incubated for 2 h at room temperature (f22jC) with the Hermodulins at 10 to 30 ng/well/100 AL in DELFIA binding buffer. Then the plates were washed thrice with DELFIA wash buffer without detergent and incubated with 100 AL of Eu-labeled ligands at various concentrations indicated in the figures. For determining nonspecific bindings in saturation studies, replicate wells contained 5.0 Amol/L unlabeled EGF, together with Eu-EGF (EGF studies) or 10 Amol/L unlabeled NRG1-h1 (NRG1-h1 studies). For routine assays of ligand binding activities of Hermodulins, studies were done as above except that a fixed concentration of 30 nmol/L Eu-EGF alone (for total binding) or 5 Amol/L unlabeled EGF (for nonspecific binding) was used to quantify HER-1 ligand binding capacity. Similarly, to quantify HER-3 ligand binding capacity, Hermodulins were assayed with 100 nmol/L Eu-NRG1-h1 alone (for total binding) or in the presence of 10 Amol/L unlabeled NRG1-h1 (for nonspecific binding). Following ligand additions, the plates were incubated at room temperature for 2 h with gentle shaking. Then the plates were placed on ice and rapidly washed thrice with ice-cold DELFIA wash buffer containing 0.02% Tween 20 (Perkin-Elmer) to remove unbound ligand. Then DELFIA enhancement solution was added at 130 AL/well and the plates were read on a fluorescence plate reader (Envision, model 2100, Perkin-Elmer) under Eu-time-resolved filter settings. The data were analyzed using GraphPad Prism Software (GraphPad Software, Inc.) for one-site or two-site binding curve fitting to generate K D and B max (maximum bound) values. For routine assays, specific binding activities of the Hermodulins were expressed as femtomoles of ligand bound per milligram of protein or per femtomole of Hermodulin.
Purity Determination of Hermodulins by SDS-PAGE and Western Blots
SDS-PAGE and Western blots were done using NuPAGE Novex Bis-Tris (4 -12%) gels (Invitrogen) and MES running buffer under reducing conditions as described by the manufacturer. For SDS-PAGE, 2.0 Ag of protein were loaded per lane and visualized with SimplyBlue SafeStain (Invitrogen). In the case of Western blots, 0.2 Ag of protein was loaded per lane and gels were blotted onto nitrocellulose. Afterwards, blots were exposed to either antihEGFR goat IgG or anti-hErbB3 goat IgG (R&D Systems) as primary antibody. Following this, a HRP-conjugated donkey anti-goat IgG from Santa Cruz Biotechnology, Inc., was used as a secondary antibody. Detection was done using the enhanced chemiluminescence plus system (GE Healthcare) and images were taken on a Typhoon Trio instrument using ImageQuant software (GE Healthcare).
Anti-Phosphotyrosine Western Blot Method for HER Family Proteins
To determine whether RB200 inhibits EGF-or NRG1-h1 -stimulated phosphorylation of HER family proteins, tumor cell lines A431, SK-BR-3, and MCF7 were used, which have high levels of HER-1, HER-2, and HER-3, respectively. The cells were plated in 10-cm Petri dishes, grown overnight, then switched to serum-free DMEM containing 0.1% bovine serum albumin for 48 h. The medium was adjusted to 2.0 mL and the cells were incubated with or without RB200 at either 0.1 or 3.0 Amol/L at 37jC for 30 min, then treated with or without growth factors, 3 nmol/L EGF, or 1.0 nmol/L NRG1-h1 for 10 min at 37jC. The cells were washed with PBS, then scraped with 1.0 mL of ice-cold HNTG buffer [50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 1.0% Triton X-100, 1.0 mmol/L EDTA, and 10% glycerol] containing Protease Inhibitor Cocktail. The cell lysates were centrifuged and clarified with protein A-Sepharose beads overnight at 4jC. The clarified cell lysates were incubated (5 Ag/sample) with anti-EGFR, anti -HER-2, or anti -HER-3, then with protein A-Sepharose beads for 16 h at 4jC. The immunoprecipitated HER proteins (200 Ag/lane) were subjected to SDS-PAGE (as above) and Western blot with anti-PY-HRP, followed by enhanced chemiluminescence plus detection (GE-Amersham), and image was visualized on Typhoon Trio instrument (GE-Amersham). To probe the HER proteins with their specific antibodies, the nitrocellulose blots were stripped of anti-PY-HRP with 62.5 mmol/L Tris-HCl (pH 7) containing 2% SDS and 0.1 mol/L 2-mercaptoethanol for 30 min at 55jC, washed, and then probed with anti-EGFR or anti -HER-2, or with anti -HER-3 and antigoat IgG-HRP (Santa Cruz Biotechnology). The Western blot image was visualized as above.
Phosphotyrosine ELISA for HER Family Proteins Cells (5,000 -20,000 per well) were plated in 96-well plates, grown overnight, and then serum starved for 24 h. The cells were then incubated with inhibitors (RB200, trastuzumab, or C225) for 30 min at 37jC, 5% CO 2 , followed by stimulation of HER family protein phosphorylation with growth factors (3 nmol/L EGF or 1 nmol/L NRG1-h1) for 10 min at 37jC. The cells were washed with ice-chilled PBS and lysed with ice-cold cell lysis buffer (Cell Signaling; 100 AL/well) containing Phosphatase Inhibitor Cocktail Set I and Set II (EMD Biosciences) and Protease Inhibitor Cocktail (Sigma-Aldrich) for 30 min on ice. In initial studies, we discovered carryover of RB200 in lysates derived from cells treated with RB200. This level of RB200 competed with cellular HER-1 binding to its capture antibody on ELISA plates. This competition by RB200 was eliminated by clarifying the cell lysates with protein A-Sepharose beads (20 AL/well of 50% slurry) overnight at 4jC. The lysate/protein A beads were centrifuged and the supernatant (protein A -treated cell lysate termed Prt-A CL) was used for phosphotyrosine ELISA.
The following anti-HER extracellular domain capture antibodies were used: for HER-1 detection, 0.4 Ag/mL antihuman EGFR antibody; for HER-2 detection, 4 Ag/mL human anti-ErbB2 capture antibody for studies with RB200 and 2 Ag/mL antihuman ErbB2 antibody for studies with trastuzumab or C225 (the murine parent of cetuximab); for HER-3 detection, 4 Ag/mL human ErbB3 DuoSet IC. All capture antibodies at the above indicated concentrations were coated at 100 AL/well in 4HXB Immulon 96-well plates. Prt-A CL, processed as above, was applied to the coated plates and incubated overnight at 4jC. Tyrosine phosphorylation on HER proteins was detected with anti-PY-HRP conjugate (R&D Systems) according to the manufacturer's instructions and with TMB chromogenic substrate (Sigma-Aldrich). Absorbance was read on a VERSAmax microplate reader (Molecular Devices) at 650 nmol/L. Inhibition of phosphorylation of HER family protein by RB200 data was expressed as a ''HER inhibition index.'' This measures the average percent inhibition of HER family proteins and is derived as follows: HER inhibition index = (% inhibition of ligand-stimulated phosphorylation of [(HER-1 + HER-2 + HER-3) / 3]).
Cell Proliferation Assays
Cell proliferation studies were conducted in either serum-containing or serum-free medium as indicated. Cells were plated in 96-well tissue culture plates (Falcon #35-3075, Becton Dickinson, NJ) at 2,000 to 6,000 per well, grown overnight, then treated with or without compounds and grown for 3 to 5 d. The effect of RB200 on growth factor (EGF or NRG1-h1) -or GPCR-ligand (LPA) -stimulated proliferation was studied under serum-free growth conditions as follows: (a) After plating in serum, the cells were grown overnight; (b) the cells were then switched to serumfree medium and grown for 24 to 48 h (serum-starvation); and (c) the cells were then treated with growth factors or LPA and with or without RB200 for 3 to 5 d. Unless stated otherwise, cell proliferation was quantified by the crystal violet dye method as previously described (24) . In some instances (indicated in the figure legends), cell proliferation was determined by 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay using Promega Cell Titer96 Aqueous One Solution assay kit. On the day of the assay, Cell Titer96 One Solution was added at 20 AL/well to the 96-well assay plate containing cells and 100 AL/well culture medium. Plates were incubated at 37jC for 15 to 30 min, then absorbance read at 490 nm using a plate reader.
Determination of Antitumor Activity In vivo In vivo antitumor efficacy studies with A431 xenografts were conducted by PRECOS at the University of Nottingham, Nottingham, United Kingdom, under the regulatory guidelines of United Kingdom Home Office Animals (Scientific Procedures) Act, 1986. MF-1 nude mice (Harlan), 4 to 6 wk old at the start of the study, were used for the tumor model. The H1437 non -small-cell lung cancer xenograft studies were done in CD-1 nu/nu nude female mice, conducted by Receptor BioLogix at the Palo Alto Medical Foundation (Palo Alto, CA) under the regulatory guidelines of OLAW Public Health Service Policy on Humane Care and Use of Laboratory Animals (1996) and under the Institutional Animal Care and Use Committee guidelines of the Palo Alto Medical Foundation. Pilot toxicity studies of RB200 were done in groups of two mice and the treatment group received 30 mg/kg RB200, i.p., thrice weekly for 2 wk. Animals were weighed daily for the duration of the study. Efficacy studies of RB200 were done in groups of 10 mice. Cells were suspended in sterile PBS, then injected s.c. into mice at 1 Â 10 7 (for A431 xenograft) or 6 Â 10 6 (for H1437 xenograft) in 100-AL volume. Tumor measurements were done using a caliper and tumor volume was calculated from the length, width, and cross-sectional area. Treatment began when the mean tumor volume reached f50 mm 3 . Mice were dosed with RB200 at either 10 or 30 mg/kg i.p. in 150-AL volume per injection, thrice weekly for 3 wk. At termination of the study, mice were anesthetized (Hyponorm/Hynovel) and 1.0 mL of blood was removed by cardiac puncture, processed for plasma, and stored frozen. For the therapeutic study, the tumors were excised, weighed, measured, and fixed in formalin.
Results
Cloning, Expression, and Screening for Hermodulins That Bind HER-1 and HER-3 Ligands
Candidate HER ligand binding molecules (Hermodulins) were transiently expressed in 293T cells and conditioned media and were tested for ligand binding ( Fig. 1 ; Table 1) . From this initial screen, we elected to pursue the HER-1:HER-3 heterodimer termed RB200, which binds both EGF and NRG1-h1. RB200 was purified using a combination of Protein-A, Ni-Sepharose, and EGFR-Affibody columns. As shown by analytic reverse-phase high-performance liquid chromatography chromatogram, the final RB200 contains no more than 10% combined contamination with HFD100 and HFD300 (Fig. 2) . In addition, the HFD100 and HFD300 elution peaks were verified by Western blot with the respective anti -HER-1 or anti -HER-3 specific antibodies (Fig. 2) . Because RB200 is a heterodimer of HER-1 and HER-3, it reacted with both anti -HER-1 and anti -HER-3 antibodies (Fig. 2) . This purified RB200 was used for the ligand binding and cell-based studies described below.
Hermodulin RB200 Binds EGF and NRG1-B1 with High Affinity
Binding studies were done to determine the affinity of growth factor ligands for RB200 using the DELFIA method. The binding affinities (K D ) of EGF or NRG1-h1 were determined using lanthanide (Eu)-labeled ligands (Eu-EGF or Eu-NRG1-h1) over a wide range of concentrations ( Fig. 3A and B) . RB200 bound both Eu-EGF and Eu-NRG1-h1 in a saturable manner. The bindings of the Eulabeled ligands could be displaced by their respective unlabeled ligands, indicating that the binding is specific (Fig. 3A and B) . The DELFIA data for binding of Eu-EGF or Eu-NRG1-h1 to RB200 are consistent with the results of direct cross-linking of 125 I-EGF or 125 I-NRG1-h1 to RB200 (Fig. 1B) . The K D for Eu-EGF or NRG1-h1 by DELFIA was f10 nmol/L. Taken together, the data show that RB200 binds both HER-1 and HER-3 ligands.
A Diverse Range of HER-1 and HER-3 Ligands Bind to RB200
In these studies, the binding ability of a ligand was tested by its ability to displace either Eu-EGF or Eu-NRG1-h1 bound to RB200. As shown in Fig. 3C , unlabeled EGF, HB-EGF, and transforming growth factor-a, but not NRG1-h1, inhibited Eu-EGF binding with an EC 50 of 5.4, 60, and 34 nmol/L, respectively, indicating that these HER-1 ligands bind to RB200. In similar studies, NRG1-a, NRG1-h3, and NRG1-h1, but not EGF, inhibited Eu-NRG1-h1 binding to RB200, with an EC 50 of 1,000, 69, and 498 nmol/ L, respectively, indicating that these neuregulins bind to RB200 (Fig. 3D) . Because unlabeled EGF did not compete with binding of Eu-NRG1-h1, and unlabeled NRG1-h1 did not compete with Eu-EGF, we conclude that the HER-1 and HER-3 ligand binding sites are independent. The competition studies also show that unrelated peptide hormone or growth factors such as insulin or IGF-I do not bind to RB200 (Fig. 3C and D) . The data show that HER-1 and HER-3 extracellular domains in RB200 are functional in ligand binding ability, retain specificity, bind multiple ligands, and suggest that the molecule can simultaneously bind both HER-1 and HER-3 ligands.
Hermodulin RB200 Inhibits EGF-or NRG1-B1^Stimu-lated HER Family ProteinTyrosine Phosphorylation
Studies were done to determine whether RB200 would block ligand-induced stimulation of tyrosine phosphorylation of HER family proteins by Western blot method. HER-1 phosphorylation was studied in A431 cells, HER-2 in SK-BR-3 cells, and HER-3 in MCF7 cells, which have high levels of the corresponding HER protein. As shown in Fig. 4A , RB200 inhibits EGF-stimulated HER-1 or HER-2 phosphorylation. EGF-induced stimulation of HER-2 phosphorylation in SK-BR-3 cells and other cell lines (discussed below) was consistently observed. Similarly, RB200 inhibited NRG1-h1 -stimulated HER-3 phosphorylation (Fig. 4A) . The Western blot data show that RB200 inhibits ligand-stimulated HER-1, HER-2, and HER-3 protein phosphorylation.
To determine whether RB200 has similar effects in other cell lines and to study this over a wider dose range, an antiphosphotyrosine ELISA method specific for each HER family member was used (see Materials and Methods). The ELISA method is more sensitive and is of higher throughput than the Western blot method and gave similar results (see below). This was studied first with A431 cells, which have high levels of HER-1 and low levels of HER-2 and HER-3. EGF treatment of A431 cells resulted in stimulation of tyrosine phosphorylation of all three HER proteins. HER-1 -associated phosphotyrosine stimulation was f10-fold, followed by HER-2 (4-fold) and HER-3 (2-fold; data not shown). EGF stimulated phosphorylation of HER-1 by 2-to 10-fold in all cell lines tested, but it stimulated HER-2 phosphorylation by 1.6-to 4-fold only in A431, HT-29, SK-BR-3, and ZR-75-1 cells tested, and not in A549 or N87 cells. HER-3 phosphorylation was stimulated 2-to 3-fold by EGF only in A431 and SK-BR-3 cells. In EGF-stimulated A431 cells, RB200 inhibited tyrosine phosphorylation of HER-1, HER-2, and HER-3 proteins in a dose-dependent manner by the ELISA method (Fig. 4B) . The greatest response with RB200, f75% inhibition with an EC 50 of 160 nmol/L, was observed for HER-1 phosphorylation (Fig. 4B) . This inhibitory effect of RB200 on EGFstimulated phosphorylation was observed in all cell lines tested, as listed in Table 2 . Because growth factors such as EGF induce heteroassociation of HER family receptor proteins and induce transphosphorylation of their respective partners (1), it is important to assess the inhibitory efficacy of candidate therapeutics on the three HER family members, HER-1, HER-2, and HER-3. This was assessed by HER inhibition index, which measures the average percent inhibition of HER family protein phosphorylation (compared with growth factor alone) and is described in Materials and Methods. The HER inhibition index for RB200 in EGF-stimulated A431 cells was 70%, indicating an effective blockade of EGF-induced signaling of HER proteins (Table 2) . In another tumor cell line, ZR-75-1 breast cancer cells (which have low levels of HER-1 but moderate levels of HER-2 and HER-3), RB200 inhibited EGF-stimulated HER-1 and HER-2 phosphorylation by 40% and 20%, respectively, with a HER inhibition index of f20% and an EC 50 of 50 to 100 nmol/L ( Fig. 4C ; Table 2 ). In ZR-75-1 cells, there was no significant increase in HER-3 phosphorylation following EGF stimulation and no effect on HER-3 phosphorylation by RB200 in EGF-treated cells.
NRG1-h1 treatment of A431 cells resulted in f2-to 4-fold stimulation of HER-3 tyrosine phosphorylation. This level of stimulation by NRG1-h1 was seen in other cells except for ZR-75-1, in which NRG1-h1 produced f7-fold stimulation of HER-3 phosphorylation. In most tumor cells studied, NRG1-h1 stimulated phosphorylation of HER-2, but stimulation of HER-1 phosphorylation was observed only in some tumor cell lines tested. In NRG1-h1 -stimulated A431 or ZR-75-1 cells, RB200 caused a dosedependent inhibition of HER-3 phosphorylation to a maximum inhibition of 60% to 80%, with an EC 50 of f120 nmol/L and a HER inhibition index of 45% to 60% ( Fig. 4C; Table 2 ). NRG1-h1 stimulation of A431 cells did not lead to any significant change in HER-1 tyrosine phosphorylation, hence no effect of RB200 on tyrosine phosphorylation of HER-1 was observed. On the other hand, NRG1-h1 treatment of ZR-75-1 cells resulted in stimulation of HER-1, HER-2, and HER-3 tyrosine phosphorylation, which was inhibited by RB200 by 40% to 60%, with a HER inhibition index of f50% and an EC 50 of 24 to 90 nmol/L, depending on the HER protein ( Fig. 4C; Table 2 ). Similar studies with RB200 were conducted with other tumor cell lines, and RB200 inhibited EGF-or NRG1-h1 -stimulated phosphorylation in a diverse range of tumor cells as well ( Table 2) .
The effects of other biologics (C225, trastuzumab, and 2C4) directed at HER family proteins were compared with that of RB200. C225, which binds HER-1, caused dosedependent inhibition of EGF-stimulated HER-1 tyrosine phosphorylation with an EC 50 of f8 nmol/L and a maximum effect of 40% to 80% inhibition in A431 and ZR-75-1 cells ( Fig. 4B and C; Table 2 ). However, unlike RB200, C225 did not inhibit NRG1-h1 -stimulated phosphorylation of HER family proteins in any of the cell lines tested ( Fig. 4B and C; Table 2 ). In A431 cells, trastuzumab, directed at HER-2, produced a low-level inhibition (f20%) of HER-2 or HER-3 phosphorylation only, whereas in NRG1-h1 -stimulated cells only, HER-3 phosphorylation was inhibited by f30% ( Fig. 4B; Table 2 ). In contrast to the above, in EGF-stimulated ZR-75-1 cells, trastuzumab did not inhibit HER family protein phosphorylation but instead was associated with f60% stimulation of HER-2 phosphorylation ( Fig. 4C; Table 2 ). However, in NRG1-h1-stimulated ZR-75-1 cells, trastuzumab inhibited HER-3 phosphorylation by 50% ( Fig. 4C; Table 2 ). Inhibition of HER-3 tyrosine phosphorylation to low levels (20 -30%) by trastuzumab, particularly in NRG1-h1 -stimulated cells, was consistently observed in all cell lines tested (A431, A549, HT-29, N87, SK-BR-3, and ZR-75-1). Studies were also done with 2C4 monoclonal antibody directed at HER-2, but with a different epitope than trastuzumab (10, 25) . In studies with either EGF-or NRG1-h1 -stimulated SK-BR-3 and ZR-75-1 cells, 2C4 inhibited this ligand-stimulated phosphorylation of HER-1 by f20% to 75% in both cells, whereas there was f20% stimulation of HER-3 and no effect on HER-2 phosphorylation (data not shown). In follow-up studies, we found that 2C4 inhibited cellular HER-2 binding to several capture antibodies used in the ELISA (data not shown).
Similar studies of ligand-stimulated phosphorylation by RB200, trastuzumab, and C225 were done with other cell lines as well. The data are summarized in Table 2 as HER inhibition index. Whereas C225 was as efficacious as RB200 in inhibiting EGF-stimulated phosphorylation of HER family proteins, it was not efficacious in inhibiting NRG1-h1 -stimulated HER protein phosphorylation. With NRG1-h1 -stimulated cells, only RB200 was effective in suppressing phosphorylation of all HER family proteins as judged by the HER inhibition index ( Table 2) . Taken together, the data show that RB200, but not C225 or trastuzumab, can compete with the cellular receptor for binding ligand and block both EGF-and NRG1-h1 -stimulated tyrosine phosphorylation of HER-1, HER-2, and HER-3.
Hermodulin RB200 Inhibits Both Growth FactorŜ timulated and Unstimulated Cell Proliferation in Monolayer Cultures
Because RB200 sequesters both EGF and NRG1-h1 and inhibits growth factor -stimulated HER family protein tyrosine phosphorylation, we tested whether it would also inhibit growth factor -stimulated cell proliferation. EGF-or NRG1-h1 -stimulated cell proliferation was studied in MCF7 cells under serum-free conditions. NRG1-h1 stimulated proliferation of MCF7 cells in a dose-dependent manner to a maximum of 50% with an ED 50 of 0.1 nmol/L, whereas EGF stimulated cell proliferation to a maximum of 30% with an ED 50 of 1.0 nmol/L. RB200 inhibited both EGF-and NRG1-h1 -induced MCF7 cell proliferation in a dose-dependent manner (Fig. 5A) . In growth factorunstimulated MCF7 cells, RB200 by itself did not cause significant inhibition (<10%) of cell proliferation (Table 3) . To determine whether the inhibition by RB200 of growth factor -stimulated MCF7 cell proliferation was specific to growth factors that bind RB200, we tested the ability of RB200 to block IGF-I -stimulated cell proliferation. IGF-I does not bind RB200 (Fig. 3C and D) . In serum-free conditions, IGF-I stimulated MCF7 cell proliferation in a dose-dependent manner to a maximum of 30% with an ED 50 of 1.0 nmol/L. In MCF7 cells stimulated to a maximum by IGF-I (10 nmol/L), RB200 did not block IGF-I -induced cell proliferation (Fig. 5A) , indicating that the effect of RB200 of abrogating growth factor -induced cell proliferation is specific to ligands that bind to RB200.
An important physiologic source of available growth factors is derived via GPCR-ligand stimulation with the serum component LPA, which induces GPCR-mediated activation of ADAM (a disintegrin and metalloproteinase) metalloproteinases (ADAM matrix metalloproteinases) on the cell surface and is a useful surrogate for the in vitro monitoring of autocrine growth control (26, 27) . The ADAM matrix metalloproteinases process the transmembrane precursors of growth factors such as amphiregulin, HB-EGF, or transforming growth factor a, with eventual release of these growth factors (13, 26 -28) . The growth factors thus generated are then available to stimulate cell proliferation. Because RB200 binds both HER-1 and HER-3 ligands, it may block this source of growth factors from tumor cells and lead to growth inhibition in this autocrine system. As shown in Fig. 5A , LPA treatment stimulated proliferation of SUM149 cells (29) ; RB200 completely blocked this LPA-stimulated proliferation.
We tested the ability of RB200 to inhibit monolayer cell proliferation in the presence of serum and without exogenously added growth factors. RB200 inhibited proliferation of A431 epidermoid cancer, MDA-MB-468 breast cancer, and H1437 non -small-cell lung cancer cells in a dose-dependent manner, with an EC 50 of 70, 1.3, and 15.0 nmol/L, respectively (Fig. 5B) . Several other tumor cell lines in monolayer culture were screened for sensitivity to RB200. A diverse range of tumor cells, including skin, breast, and lung cancer cells, are growth inhibited by RB200 (Table 3) . However, some tumor cell lines, including breast, lung, colon, and gastric cancer cells, are not sensitive to growth inhibition by RB200 (Table 3) . HER-2 kinases (3, 30) . Thus, we conducted combination studies of RB200 with tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva; EGFR kinase inhibitors), lapatinib (Tykerb; a HER-2 and HER-1 kinase inhibitor), and imatinib (Gleevec; bcr-abl kinase inhibitor). We also studied a tyrphostin (AG-825) that preferentially targets the HER-2 -associated tyrosine kinase (31) . These combination studies of RB200 and tyrosine kinase inhibitors were done in the monolayer cell proliferation assay. RB200 or AG-825 alone inhibited H1437 (non -small-cell lung cancer) cell growth to low levels (10 -15%), but the combination produced a marked synergy, f50% growth inhibition (Fig. 6) . The synergy data were analyzed with CalcuSyn (Biosoft) for determination of synergy in drug combination studies (32) . The data are presented as combination index (CI), where CI < 1.0 indicates synergy between two compounds, CI = 1 is indicative of additive response, and CI > 1 is indicative of antagonism or less than additive response between the compounds.
For AG-825, combination with RB200 was synergistic at all concentrations tested with a CI of 0.2. Gefitinib (directed toward the EGFR tyrosine kinase) was also highly synergistic with RB200, with a CI of 0.2 in MDA-MB-468 breast cancer cells. This synergy with RB200 was also observed with erlotinib, another EGFR kinase inhibitor, in HT-29 colon tumor cells (Fig. 6 ). In contrast, in nontransformed cell line Hs578 Bst, RB200 had no significant inhibition of cell proliferation and showed no synergy with gefitinib (Fig. 6) . Results of studies on synergy between RB200 and tyrosine kinase inhibitors for other cell lines are summarized in Table 4 . The data show that RB200 is synergistic with other tyrosine kinase inhibitors such as lapatinib (HER-2 kinase inhibitor) and erlotinib (HER-1 kinase inhibitor; Table 4 ). Moreover, RB200 was synergistic with AG-825 and with gefitinib in a diverse range of tumor cell lines, although some tumor cells do not show synergy with these compounds (Table 4) . However, imatinib (bcr-abl kinase inhibitor) showed moderate synergy with RB200 only in A431 cells, but no synergy in other cell lines, suggesting that synergy with RB200 may be primarily associated with blockade of the HER-1/HER-2 signaling pathways. Taken together, the data show that RB200, at very low doses, synergizes the growth-inhibitory activities of tyrosine kinase inhibitors directed toward HER-1 or HER-2 kinases.
RB200 Has In vivo Antitumor Efficacy inTwo Human Tumor Xenograft Models
In vivo efficacy of RB200 was tested in A431 human epidermoid carcinoma and H1437 non -small-cell lung cancer xenografts in nude mice. These models were chosen because RB200 was shown to have a direct antiproliferative effect on each cell type in vitro (Fig. 5B) . In both models, tumors were allowed to grow in mice s.c. for 1 week, followed by dosing of RB200 at 10 or 30 mg/kg thrice weekly for 2 weeks. In the A431 tumor xenografts, the higher dose of RB200 (30 mg/kg) gave a statistically significant (P = < 0.01) inhibition of tumor growth (50%) following 2 weeks of treatment (Fig. 7A) . RB200 was more active in the H1437 non -small-cell lung cancer xenograft model than in the A431 model, but was given from day 0, with f70% inhibition of tumor growth after 2 weeks of treatment (Fig. 7B) . Additionally, cetuximab (3 mg/kg), a monoclonal antibody directed to EGFR, was not active in the H1437 xenograft model (Fig. 7B) . In a similar H1437 xenograft model, cetuximab at 12 mg/kg dose was not active; tumor growth was the same as in the PBS vehicle. The plasma concentration of RB200 in mice at 24 h post i.p. dose of 30 mg/kg was 14.7 F 3 Ag/mL as determined by the ELISA method. This corresponds to a RB200 plasma concentration of f80 nmol/L, which is within the 15 to 70 nmol/L concentration range where growth inhibition of H1437 and A431 cells, respectively, was observed during in vitro proliferation assays (Fig. 5B) . Thus, the in vivo responses of these tumor xenografts correlated with their in vitro sensitivity (Fig. 5B) .
Discussion
Data presented here describe the potential therapeutic utility of a heterodimeric HER-1/Fc:HER-3/Fc chimeric fusion protein (RB200). RB200 binds both HER-1 and HER-3 ligands, blocks EGF-and NRG1-h1 -stimulated receptor tyrosine phosphorylation of HER family proteins in cells, and inhibits ligand-stimulated tumor cell proliferation, including LPA-stimulated cell growth. Furthermore, RB200 is synergistic with tyrosine kinase inhibitors directed toward EGFR/HER-1 and HER-2 kinases with respect to tumor cell proliferation in vitro. RB200 also has in vivo antitumor activity in two human tumor xenograft models. Their studies showed that natural HER extracellular domains bind ligands. The present study is the first demonstration that a HER-1/Fc:HER-3/Fc heterodimeric construct (RB200) can bind both HER-1 and HER-3 ligands. We showed this by two different ligand binding methods: first by ligand cross-linking studies and second by saturation binding using Eu-labeled ligands and the DELFIA method. Ligand competition studies indicated that multiple HER-1 and HER-3 ligands bind to RB200. Ligands that bind other receptors (insulin and IGF-I) did not compete for natural ligand binding to RB200, suggesting that it retained its specificity. Furthermore, based on our findings that NRG1-h1 did not compete with Eu-EGF binding and that EGF did not compete with Eu-NRG1-h1 binding, it was shown that the HER-1 and HER-3 ligand binding sites are independent from each other, implying that RB200 can simultaneously bind both HER-1 ligands and HER-3 ligands. Previous reports on ligand binding to the EGFR extracellular domain have shown that it exists in a highaffinity population with a K D of 2 to 20 nmol/L and in a low-affinity population with a K D of f500 nmol/L (35, 36) . We report here that the HER-1 arm in the RB200 heterodimer exists in the high-affinity form with a K D of f10 nmol/L. The K D for NRG1-h1 binding to HER-3/IgG homodimeric construct has been reported to be 9 nmol/L (33, 34). However, heterodimerization of HER-3 with HER-2, as in HER-2/IgG:HER-3/IgG, revealed a very high-affinity population with a K D of 0.013 nmol/L and a low-affinity site with a K D of 6.5 nmol/L for NRG1-h1 (33) . These data suggest that the HER-3 arm in the heterodimer RB200 retains its intrinsic high affinity for NRG1-h1.
EGF stimulation of tumor cells results in increased tyrosine phosphorylation of HER-1, HER-2 and HER-3, with the greatest stimulation in phosphorylation associated with HER-1. RB200 inhibited the EGF-stimulated phosphorylation of all three HER proteins. Similarly, RB200 inhibited NRG1-h1 -stimulated phosphorylation of HER proteins, most dramatically in HER-3. Inhibition of EGFand NRG1-h1 -stimulated HER-1, HER-2, and HER-3 phosphorylation was inhibited more effectively by RB200 compared with monoclonal antibodies that specifically target HER-1 (C225) or HER-2 (trastuzumab and 2C4). In addition to inhibition of ligand-stimulated HER family protein phosphorylation, RB200 inhibited EGF-and NRG1-h1 -stimulated, but not IGF-I -stimulated, cell proliferation. This finding suggests that RB200 blocks these cellular effects by a HER family -specific ligand trap mechanism. Although studies on inhibition of growth factor -stimulated cell proliferation by RB200 were done in serum-free cultures, several tumor cell lines grown in serum were also sensitive to growth inhibition by RB200. This inhibition of tumor cell proliferation by RB200, in the absence of exogenously added growth factors, suggests that either HER-1 or HER-3 ligands are present in the serum or these tumor cells may produce HER-1 or HER-3 ligands in an autocrine manner and are at least partially dependent on these growth factors for continued proliferation. Another possible mechanism is that RB200 may bind to the transmembrane HER-1 or HER-3 proligands, thus preventing juxtacrine stimulation and consequently inhibiting cell proliferation. For example, etanercept (Enbrel), an Fc-fusion homodimeric tumor necrosis factor-a receptor, binds transmembrane tumor necrosis factor-a with high affinity (37) . The data indicate that RB200 sequesters multiple HER-1 and HER-3 ligands in cell-based phosphorylation and proliferation assays. A large body of evidence indicates that a major endogenous source of growth factor ligands for tumor cells is generated via GPCR-ligand activation of ADAM matrix metalloproteinases, which proteolytically shed the transforming growth factor and HB-EGF precursors from tumor or stromal cells (13, 26 -28) . In this study, we have shown that the GPCRligand (LPA) -stimulated proliferation of several tumor cells was blocked by RB200, suggesting that the Hermodulin may sequester this endogenous source of growth factor ligands (Fig. 5) . One possible mechanism whereby RB200 blocks LPA-induced cell proliferation may be that it acts as a receptor decoy for GPCR-ligand -induced release of membrane-anchored HER-1 and HER-3 proligands; another possible mechanism is that RB200 may bind the proform of transmembrane growth factors and prevent their cleavage and release by matrix metalloproteinases. Future studies will be directed to elucidate these possible mechanisms of action of RB200 and to optimize its binding characteristics.
The optimum therapeutic efficacy of many biologics is achieved in combination with chemotherapeutics (3, 30) . In this study, we have shown that RB200 is synergistic with HER-1 -and HER-2 -directed tyrosine kinase inhibitors such as AG-825, erlotinib, gefitinib, or lapatinib. It is important to note that in non -small-cell lung cancer cells such as H1437 or Calu-6, which are relatively resistant to HER-1 tyrosine kinase inhibitors, RB200 exhibited strong synergy with HER-1 and HER-2 tyrosine kinase inhibitors (Table 4) . One possible mechanism of synergy between RB200 and tyrosine kinase inhibitors directed to HER family members is that RB200 acts as a ligand trap for either soluble or transmembrane growth factors. Another possibility is that HER family -directed tyrosine kinase inhibitors, when bound to the tyrosine kinase domain, may decrease the ligand binding affinity of HER proteins, thus allowing RB200 to better compete with transmembrane receptors in ligand binding. , the mice were treated with PBS vehicle (n), RB200 at 3 mg/kg (E) or 15 mg/kg (.), or cetuximab at 3 mg/kg (!), administered i.p. thrice weekly for 3 wk. Arrows, time of injections. There were 10 mice per each treatment group. Points, mean tumor volume; bars, SE. *, P < 0.01.
